Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?

@inproceedings{Shakespeare2016CanWA,
  title={Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?},
  author={Thomas Philip Shakespeare and Shea W Wilcox and Noel J. Aherne},
  booktitle={OncoTargets and therapy},
  year={2016}
}
AIM Both dose-escalated external beam radiotherapy (DE-EBRT) and androgen deprivation therapy (ADT) improve outcomes in patients with high-risk prostate cancer. However, there is little evidence specifically evaluating DE-EBRT for patients with high-risk prostate cancer receiving ADT, particularly for EBRT doses >74 Gy. We aimed to determine whether DE-EBRT >74 Gy improves outcomes for patients with high-risk prostate cancer receiving long-term ADT. PATIENTS AND METHODS Patients with high… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.

  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2015
VIEW 1 EXCERPT